Last reviewed · How we verify
LNG-IUS (BAY 86-5028) — Competitive Intelligence Brief
phase 3
Intrauterine contraceptive device (IUD)
Progesterone receptor (local uterine effects)
Contraception / Gynecology
Small molecule
Live · refreshed every 30 min
Target snapshot
LNG-IUS (BAY 86-5028) (LNG-IUS (BAY 86-5028)) — Bayer. LNG-IUS is a levonorgestrel-releasing intrauterine system that provides long-acting reversible contraception by releasing a synthetic progestin directly into the uterus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LNG-IUS (BAY 86-5028) TARGET | LNG-IUS (BAY 86-5028) | Bayer | phase 3 | Intrauterine contraceptive device (IUD) | Progesterone receptor (local uterine effects) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Intrauterine contraceptive device (IUD) class)
- Bayer · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LNG-IUS (BAY 86-5028) CI watch — RSS
- LNG-IUS (BAY 86-5028) CI watch — Atom
- LNG-IUS (BAY 86-5028) CI watch — JSON
- LNG-IUS (BAY 86-5028) alone — RSS
- Whole Intrauterine contraceptive device (IUD) class — RSS
Cite this brief
Drug Landscape (2026). LNG-IUS (BAY 86-5028) — Competitive Intelligence Brief. https://druglandscape.com/ci/lng-ius-bay-86-5028. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab